This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

J.P. Morgan Sticks to Its Buy Rating for Merck & Company (MRK)

Tipranks - Tipranks - Sat Aug 8, 7:18AM CDT

J.P. Morgan analyst Chris Schott maintained a Buy rating on Merck & Company yesterday and set a price target of $150.00. The company’s shares closed yesterday at $128.37.

Claim 55% Off TipRanks

According to TipRanks, Schott is a 4-star analyst with an average return of 5.7% and a 57.29% success rate. Schott covers the Healthcare sector, focusing on stocks such as Pfizer, Eli Lilly & Co, and Gilead Sciences.

In addition to J.P. Morgan, Merck & Company also received a Buy from Barclays’s Emily Field in a report issued on August 5. However, on the same day, Berenberg Bank maintained a Hold rating on Merck & Company (NYSE: MRK).

See Insiders’ Hot Stocks on TipRanks >>

Based on Merck & Company’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $16.29 billion and a GAAP net loss of $4.24 billion. In comparison, last year the company earned a revenue of $15.62 billion and had a net profit of $5.08 billion

Read More on MRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).